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Abstract: Dysregulation of matrix metalloproteinase (MMP) activity can lead to a wide range of disease states such as atherosclerosis, 
inflammation or cancer. The ability to image MMP activity non-invasively in vivo, by radiolabelled synthetic inhibitors, would allow the 
characterization of atherosclerotic plaques, inflammatory lesions or tumors. Here we present an overview of radiolabelled MMP inhibi-
tors (MMPIs) and MMP peptides for positron emission tomography (PET) and single photon emission computed tomography (SPECT) 
for the detection of proteolytic activity of MMPs. So far, most studies are at a preliminary stage; however, some hydroxamate-based trac-
ers such as the peptidomimetics [111In]-DTPA-RP782, [99mTc]-(HYNIC-RP805)(tricine)(TPPTS), or Marimastat-ArB[18F]F3 and the pico-
lyl-benzenesulfonamide [123I]I-HO-CGS 27023A identified specifically the enzymatic action of MMPs in animal models of various pa-
thologies. The development of new compounds that may lead to novel tracers (e.g. modification of zinc-binding group, variation of sub-
stituents attached to the S1’, S2’ and S3’ pockets of the MMP inhibitors) and the use of antibodies and cell penetrating peptides are also 
discussed. In general, preclinical studies with atherosclerosis models proved to be more successful than those with oncological models. 
Keywords: MMP inhibitors, MMP peptides, hydroxamates, molecular imaging, PET, SPECT. 
1. INTRODUCTION 
 Zinc proteases [1]; [2]; [3], which are the best characterized 
zinc enzymes, are implicated in many physiological and pathologi-
cal processes. These proteases are a multi-domain family which is 
classified based on the structure of their catalytic sites and includes 
the metzincins, the inuzincins, the gluzincins, the carboxypepti-
dases, and DD carboxypeptidases (D-alanyl-D-alanine-cleaving 
carboxypeptidases). The metzincins are defined by a zinc binding 
consensus sequence HExxHxxGxxH which contains three histidine 
residues and a strictly conserved methionine containing tight 1,4 
beta turn (the Met-turn) forming a hydrophobic cleft for the cata-
lytic zinc ion. They are further subdivided according to the residue 
following the third histidine zinc ligand and the residues surround-
ing the methionine in the Met-turn. The metzincins comprise the 
matrixins, the serralysins, the astacins, and the adamalysins. Fi-
nally, the matrixins contain the well-known Matrix MetalloProtein-
ases or MMPs and the adamalysins, the A Disintegrin And Metal-
loproteinases or ADAMs.  
1.1. Domains of MMPs and ADAMs 
 MMPs (Fig. 1); [4] are secreted proteins with four distinct con-
served domains: the terminal pro-domain, the catalytic domain 
(which contains a Zn
2+
 ion in its active site), the hinge region and 
the terminal hemopexin domain. Except for MMP-7, MMP-23 and 
MMP-26, all MMPs contain a hemopexin carboxy-terminal do-
main. It functions as a recognition sequence for the substrate and 
stabilizes the interaction of TIMPs (Tissue Inhibitors of Matrix 
metalloProteinases) with active MMPs [5].  
 ADAMs (Fig. 1) are membrane bound metzincins. They have a 
similar structure as the MMPs. The hemopexin domain is replaced 
by a cystein-rich domain, an EGF (Epidermal Growth Factor)-like 
domain and the disintegrin domain. The cystein-rich domain and  
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the disintegrin domain allow ADAMs to interact with proteins con-
nected to the extracellular matrix (ECM) [6]. 
 Under physiological conditions, three forms of MMPs/ADAMs 
are found, two inactive and one active. The first is the pro-form in 
which the pro-domain is still present, the second form is inhibited 
by TIMPs and the third is the active form lacking the pro-domain 
and not inhibited by TIMPs [7]. The mechanism of action of cataly-
sis of protein substrates is carried out by activation of a zinc-bound 
water molecule by the carboxylate group of the conserved gluta-
mate residue in the catalytic pocket followed by attack of water on 
the polarized carbonyl group in the substrate’s scissile bond (Fig. 
2). Therefore the Zn
2+
 ion acts as a Lewis acid [8]. MMPs and AD-
AMs are activated under the influence of growth factors, hormones, 
cytokines and cellular transformation [9]. 
1.2. Classification of MMPs and ADAMs 
 In humans, MMPs form a group of 23 zinc-dependent enzymes 
(24 in mice) which are generally classified according to their sub-
strate specificity (Table 1); [10]; [11]; [12]. Approximately two-
third of the MMPs are secreted as inactive proforms and activated 
extracellularly. However MMP-11 and membrane-type MMPs are 
transmembrane metzincins.  
 In humans, 22 ADAM proteases have been identified (Table 2); 
[1]; [6]. 
1.3. Role of the MMP/ADAM family  
 MMPs and ADAMs are neutral endopeptidases which degrade 
and remodel structural proteins of the ECM [1]. They are involved 
in many physiological processes, such as embryo implantation, 
bone remodelling and organogenesis, and are implicated in the 
reorganization of tissues during pathological conditions such as 
inflammation, wound healing and invasion of cancer cells [10]. 
 Upregulation of MMP-2 and MMP-9 is associated with poor 
prognosis in oncology; therefore, these enzymes are the most 
widely studied metalloproteinases. MMP-2 degrades type IV colla-
gen and promotes angiogenesis and mitogenesis. The enzyme is 
overexpressed in many human malignancies and has been associ-
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A: pro-domain, B: catalytic domain, C: hinge region, D: hemopexin domain, E: transmembrane domain, F: cytoplasmic tail, G: disintegrin  domain; H: cystein-
rich domain; I: EGF (Epidermal Growth Factor)-like domain. 
Fig. (1). Schematic representation of the domain structure of MMPs, MT-MMPs and ADAMs 
 
Table 1. Classification of the 23 Identified Human MMPs 
MMP No. Enzyme Nomenclature Principal Substrate(s)
a
 Secreted or Transmembrane Metzincins 
MMP-1 Collagenase-1 -   
Interstitial collagenase 
Collagen types I, II, III, VII, and X Secreted  
MMP-8 Collagenase-2 -  
Neutrophil collagenase 
Collagen types I, II, III, VII, and X Secreted  
MMP-13 Collagenase-3 Collagen types I, II, III, VII, and X Secreted  
MMP-2 Gelatinase A -  
72 kDa type IV collagenase 
Gelatin types I, IV, V, and X; laminin V Secreted  
MMP-9 Gelatinase B -  
92 kDa type IV collagenase 
Gelatin types I, IV, V, and X; laminin V Secreted  
MMP-3 Stromelysin-1 -   
Transin-1 
Collagen types III, IV, IX, and X; gelatine; pro-
MMP-1; laminin; and proteoglycan 
Secreted  
MMP-10 Stromelysin-2 Collagen types III, IV, IX, and X; gelatin, pro-
MMP-1; laminin; and proteoglycan 
Secreted  
MMP-11 Stromelysin-3 -1-antiprotease Transmembrane  
MMP-12 Metalloelastase -   
Macrophage metalloelastase 
Elastin Secreted  
MMP-7 Matrilysin-1 -   
Pump-1 
Gelatin, fibronectin and pro-MMP-1 Secreted  
MMP-26 Matrilysin-2 -   
Endometase 
To be determined Secreted  
MMP-14 Membrane type-1 MMP -   
MT1 MMP 
Pro-MMP-2, gelatin, and collagens Transmembrane  
MMP-15 Membrane type-2 MMP -   
MT2 MMP 
Pro-MMP-2 Transmembrane  
MMP-16 Membrane type-3 MMP -   
MT3 MMP 
Pro-MMP-2 Transmembrane  
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MMP No. Enzyme Nomenclature Principal Substrate(s)
a
 Secreted or Transmembrane Metzincins 
MMP-17 Membrane type-4 MMP -   
MT4 MMP 
To be determined Transmembrane  
MMP-24 Membrane type-5 MMP -   
MT5 MMP 
To be determined Transmembrane  
MMP-25 Membrane type-6 MMP -   
MT6 MMP 
To be determined Transmembrane  
MMP-19 Human orthologue of Xenopus Gelatin Secreted  
MMP-20 Enamelysin Amelogenin (dentine), gelatin Secreted  
MMP-21 Human orthologue of Xenopus To be determined Secreted  
MMP-23 Cysteine array MMP -   
Femalysin 
To be determined Secreted  
MMP-27 None To be determined Secreted  
MMP-28 Epilysin To be determined Secreted  
 
Table 2. Overview of the 22 Identified Human ADAM Proteases 
ADAM Alternative Names ADAM Alternative Names 
1 Fertilin , PH-30  17 TACE, CD156b 
Snake venom-like protease 
2 Fertilin , PH-30  
Cancer/testis antigen 15 
18 tMDC III, ADAM-27 
3 Cyritestin, tMDC I 19 Meltrin , MADDAM 
6 tMDC IV 20 None 
7 EAP-1,Sperm maturation-related glycoprotein GP-83 21 ADAM-31 
8 Cell surface antigen MS2, CD156a 22 MDC 2 
9 MDC9, Meltrin  
Myeloma cell metalloproteinase 
28 MDC-L, ADAM-23 
10 Kuzbanian protein homolog, CD16c 29 Cancer/testis antigen 73 
11 MDC 30 None 
12 Meltrin  32 None 
15 Metargidin, MDC-15 33 None 
 
ated with breast cancers that are metastatizing to the lung. In ge-
latinase A-deficient mice, tumor-induced angiogenesis was sup-
pressed, melanoma and lung cancer growth were inhibited and the 
number of lung metastases was reduced significantly [13].  
 MMP-9 exhibits both anti-cancer and tumor-promoting effects. 
In animal experiments, disturbance of MMP-9 function decreases 
tumor development whereas overexpression of MMP-9 induces 
angiogenesis and increases malignant transformation. Although 
knock-down of MMP-9 decreased the occurrence of carcinogenesis 
in certain mouse models, the tumors that were formed in MMP-9 
deficient mice were significantly more aggressive and had more 
undifferentiated phenotypes. This result suggests that MMP-9 may 
exert tumor-promoting effects early in the process of carcinogenesis 
and anti-cancer effects at later stages of the disease [13]. 
1.4. Inhibition of MMPs/ADAMs 
 Dysregulation of MMP/ADAM activity is an important aspect 
of the pathophysiology of several diseases, including atherosclero-
sis, inflammation and cancer. In addition, MMPs and ADAMs are 
upregulated in a variety of other diseases such as dermatologic, 
ophthalmic (macular degeneration), infectious, immunologic, car-
diovascular, and neurodegenerative conditions. The control of 
MMP/ADAM activity by inhibitors has therefore gained consider-
able interest as a possible therapeutic target [14]. 
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 MMPs and ADAMs are inhibited by nonspecific protease in-
hibitors such as 2-macroglobulin and 1-antiprotease, and by a 
small family of specific natural inhibitors towards metalloprotease 
activity: TIMPs. These physiological inhibitors, which form a 
group of 4 glycoproteins (TIMP 1-4) (21-30 kDa in size), have 




 M range and seem ideal 
candidates for labelling and therapy but they lack selectivity and 
possess other biological functions [10]; [15]; [16]. For instance, 
they stimulate growth of several cell types, induce changes in cell 
morphology and inhibit angiogenesis [12]. As a result, synthetic 
and more specific MMP inhibitors (MMPIs) were developed. The 
following structural features are required to design an MMPI:  
(i) at least one functional group that provides a hydrogen bond 
interaction with the enzyme backbone,  
(ii) one or more side chains, capable of van der Waals interactions 
with the enzyme subsites and  
(iii) a functional group (e.g., hydroxamate, phosphonate, carboxy-
late, thiol, barbiturate, etc.) capable of chelating the active-site 
zinc(II) ion (referred to as zinc binding group or ZBG) (Fig. 
3); [11]; [17]; [18]. 
 By structure-activity relationship (SAR) studies and combinato-
rial chemistry, a schematic representation of the binding mode of a 
peptidomimetic MMP/ADAM inhibitor (Fig. 4) was proposed. 
Three different binding pockets were defined. First of all, the S1´ 
pocket, commonly called the “selectivity pocket”, is a relatively 
deep pocket for the majority of the enzymes except for MMP-1, -7 
and -11. A “more” selective inhibitor is obtained when a large sub-
stituent (mainly hydrophobic) is attached to it while smaller P1´ 
substituents (generally aliphatic) resulted in a broad-spectrum in-
hibitor. The S2´ pocket is a solvent-exposed pocket which has more 
affinity for hydrophobic P2´ residues. Then, the S3´ pocket is an ill-
defined solvent-exposed region. Finally, activity of some MMP 
members can be increased by incorporating a substituent in the 
alpha position of the zinc-binding group of a MMPI [11]; [19]. 
1.5. Quantification of MMPs  
 Up to now, most research linking MMPs to diseases has been 
restricted to ex vivo assays on excised tissues or fluid samples using 
fluorescence detection kits, immunohistochemistry, ELISA, zy-
mography, or Western blotting, addressing the correlation between 
protein quantity (immunological assays) or expression levels 
(mRNA analysis) and disease activity or state. As proteolytic activ-
ity is highly regulated and used as a marker for certain cancer types 
or inflammation, molecular imaging of locally up-regulated and 
activated matrix metalloproteinases in vivo could be used to im-
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Fig. (4). Schematic representation of a peptidomimetic MMP/ADAM in-
hibitor. 
 
ase inhibitors, to serve as an in vivo screening tool for drug devel-
opment, to image transgene expression, or to understand how prote-
ase activities are regulated [20]. 
 Here we review MMP inhibitors, MMP peptides, antibodies, as 
well as cell-penetrating peptides for the detection of proteolytic 
activity of MMPs and ADAMs, using single photon emission com-
puted tomography (SPECT), and positron emission tomography 
(PET).  
2. PROBES FOR IMAGING MMPS 
2.1. MMP Inhibitors for PET/SPECT 
2.1.1. Natural MMP Inhibitors  
 Logically, radiolabelled endogenous TIMPs were chosen as a 
target for the diagnosis of pathologies associated with upregulated 
MMP levels. TIMPs bind noncovalently to MMPs with binding at 
very high Kd values [7]. Each TIMP is composed of two domains, 
the N- and C-terminal, which are both characterized by three disul-
fide bonds [21]. Among the TIMP family, TIMP-2 has generated 
the most interest because the N-terminal domain of TIMP-2 (N-
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Fig. (2). Mechanism of action of catalysis of protein substrates by MMPs. 
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tains inhibitory activity [22]. Moreover, N-TIMP-2 has affinities for 




 M range which is much higher than syn-
thetic MMP inhibitors (usually 10
-9
 M). TIMP-2 demonstrated posi-






 Giersing et al. [24] conjugated the N-terminal domain of re-
combinant human TIMP-2 (127 amino acids) with the bifunctional 
chelator diethylenetriamine pentaacetic acid (DTPA) followed by 
radiolabelling to obtain [
111
In]-DTPA-N-TIMP-2 1. Fluorogenic 
inhibition assay with the catalytic domain of MMP-3 (cMMP-3) 
was performed with N-TIMP-2 and 1. N-TIMP-2 and 1 inhibited 
cMMP-3 identically, which suggested no effect from the radiolabel-
ling.  
 As dysregulation of MMP expression was correlated with Ka-
posi sarcoma (KS) development and no tracer so far was able to 
detect specifically this pathology, Kulasegaram et al. [25] per-
formed a pilot study with 1 in five patients with HIV infection and 
KS. Patients did not exhibit significant retention of 1 in the estab-




 As radiolabelling of rhTIMP-2 with [
111
In]-DTPA could lead to 
a random DTPA-conjugate, Oltenfreiter et al. [26] performed iodi-
nation of rhTIMP-2 with Na
123
I in order to obtain [
123
I]-rhTIMP-2 
2. Biodistribution in NMRI mice after administration of [
123
I]-
rhTIMP-2 was performed. 2 exhibited no long-term accumulation 
in heart, lungs, liver and heart. A rapid clearance by the kidneys 
was obtained due to the low molecular weight of rhTIMP-2 (21 
kDa). The stomach showed a retention of 24.5% ID/g 1 hr p.i. sug-
gesting dehalogenation of 2. 
 Since N-TIMP-2 was shown to bind specifically MT1-MMP, 
van Steenkiste et al. [27] evaluated 2 on MT1-MMP-
overexpressing (S.1.5) and control (C.IV.3) tumor-inoculated mice. 
TIMP-1 exhibits similar binding as TIMP-2 towards soluble MMPs. 
However TIMP-1 was unable to bind MT1-MMP and was used as 
negative control. Preliminary studies with tumor-free nu/nu mice 
indicated a comparable clearance rate for 2 and [
123
I]-rhTIMP-1. 
Planar imaging allowed visualizing 2 in S.1.5 tumor in contrast to 
contralateral background areas. Each time point demonstrated sig-
nificant differences between 2 and [
123
I]-rhTIMP-1 in S.1.5 tumor 
and 2 in S.1.5 and C.IV.3 tumors. Although evaluation to demon-
strate the specificity of [
123
I]-rhTIMP-2 is necessary, 2 may be a 
potential tracer to visualize tumor associated with MT1-MMP 
overexpression. 





represent attractive tracers for imaging of MMP activity, no further 
evaluation was performed. Partially due to the difficult purification 
of N-TIMP-2, synthetic MMP inhibitors attracted much more inter-
est. 
2.2. Synthetic MMP Inhibitors with a ZBG 
 The synthetic MMPIs are classified on the basis of the group 
that binds to the zinc atom: hydroxamate, carboxylate or barbitu-
rate.  
2.2.1. Hydroxamate-based MMP Inhibitors  
 Most of the MMP/ADAM inhibitors belong to the hydroxamate 
category. Hydroxamic acid is a functional group which corresponds 
to a hydroxylamine inserted into a carboxylic acid. The hydrox-
amate is the most potent ZBG, the strength of the binding results 
from a five membered ring in which both oxygens are bound to the 
metal center [28] (Fig. 5). It acts as a bidentate ligand with the ac-
tive-site zinc ion. We subdivided these MMPIs into two categories 
























Fig. (5). Binding pose of the hydroxamate ZBG into the active site of 
MMPs. 
 
Peptidomimetic Hydroxamate Inhibitors 
 Peptidomimetics mimic the structure of collagen (a substrate of 
MMP) at the MMP cleavage site. These compounds function as 
competitive inhibitors and chelate the zinc atom of the MMP en-









 Su et al. [29] performed preliminary nonimaging studies with 
[
111
In]-DTPA-RP782 3 and the negative control [
111
In]-DTPA-
RP788 4 (Fig. 6), RP788 being the biologically inactive isomer of 
RP782. Both SPECT-tracers were tested in control mice and in 
mice one week after myocardial infarction (MI) surgery. Mi-
croautoradiography allowed the detection of [
111
In]-DTPA-RP782 
in the MI, in contrast to [
111
In]-DTPA-RP788 (Fig. 7). 3 and 4 
showed similar myocardial uptake in control mice. 
 A technetium tracer based on an analog inhibitor of 3 was syn-
thezised: [
99m
Tc]-(HYNIC-RP805)(tricine)(TPPTS) 5 (Fig. 6). 
MMP fluorogenic assays were performed on the macrocyclic in-
hibitor RP805. RP805 showed nanomolar affinities in vitro against 
MMP-2, MMP-3, MMP-7, MMP-9, MMP-12, MMP-13, ADAM-







































































































































































Fig. (6). Structure of peptidomimetic hydroxamate-based MMP inhibitors 
for PET/SPECT. 
 
Vascular Remodeling Imaging 
 Su et al. [29] evaluated 5 in mice one, two and three weeks 
after MI surgery and in control mice with microSPECT/CT. About 
5-fold increase of 5 uptake in the infarct region was obtained in 
mice having undergone MI surgery (after 1, 2 and 3 weeks) in con-
trast to control mice. Myocardial [
99m
Tc]-(HYNIC-RP805)(tricine) 
(TPPTS) activity in the remote noninfarcted area was approxi-
mately 2-fold higher than in control mice, this difference being 
statistically significantly different at two and three weeks. In con-
trol mice, immunofluorescent staining was minimal for MMP-2 and 




Fig. (7). Morphology and 3 and 4 microautoradiography of short-axis myo-




Fig. (8). Example of (A) 3 microSPECT, (B) CT angiography, and (C) 
fused microSPECT/CT in vivo imaging at 3 weeks after carotid injury. 
L: left carotid artery - R: right carotid artery. 
 
obtained for both gelatinases. Moreover, the fluorescence was sig-
nificantly related to the MI region and was confirmed by zymogra-
phy.  
 Zhang et al. [30] evaluated 3 in injury-induced vascular remod-
eling in mice. ApoE-/- mice after one week of high-cholestrol (HC) 
diet underwent left common carotid injury. The right carotid was 
used as control. Specificity of 3 was tested with a 50-fold excess of 
unlabelled precursor RP782. Staining of the carotid wire injury 
resulted in significant hyperplasia and expansive remodeling over a 
Probes for Non-invasive Matrix Metalloproteinase-targeted Current Pharmaceutical Design, 2013, Vol. 19, No. 00    7 





























[35]; [37];  
[38]; [39] 
  10.5 nM 14 nM < 6.4 
nM 
  7.4 nM  < 6.0 
nM 
7.3 nM    27 nM 95 nM 
6a [40] ; [41]   2.02 nM              
6b [40] ; [41]   7.70 nM              
6c [40] ; [41]   1.59 nM              
Br-7 [42]; [43]  0.5±0.1 
nM 
    4.9±3.1 nM      25.0±6.2nM 7.0±4.6nM   
7 [42]; [43]  0.6±0.05 
nM 
    2.4±1.4 nM      21.7±6.4 
nM 
7.3±0.6 nM   





9 [46] 43 nM 11 nM 34 nM   13 nM  27 nM  4.9 nM       
11 [46] 33 nM  20 nM 43 nM    8 nM         
12a [50]; [51]   4±3 nM   2±1 nM  50±27 nM   11±0.3 nM      
15a [54]   320 nM     153 nM         
15d [54]   2.5 nM     4.6 nM         
16 [51]; [56]   3±1 nM   2±1 nM  7±1 nM   0.8±0.03 
nM 
     
17 [50]; [57]   8±1 nM   0.9±0.3 nM  0.5±0.1 nM   0.9±0.2 nM      
18 [58]   0.13±0.07 
nM 




  0.006±0.003 
nM 
     
19 [47] 1.5 M  3 nM 8 nM 7.2 M   2.2 M   6 nM      





    239.7±15.7 
nM 





23 [42]; [43]  9.3±1.5 
nM 
    201.0±58.6 
nM 





24 [44]; [45]  23±3 nM     429±36 nM      180±45 nM 232±29 nM   
25a [61]   1.9 M              
27 [65]   7 nM     2 nM         
28 [66] > 50 
M 
 23±9 nM   138±12 nM  7±2 nM   645±17 nM 760 M     
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31 [69] ; [71]   13.2±1.6  
M 
  NI  9.6 M 11.0±2.5  
M 
 NI NI     
32 [70]   5 to 10 
M 
    50 to 100 
M 
        
33 [71]   8.7 M     8.6 M 18.2 M        
34 [71]   > 1000 
M 
     20.4 M        
35 [72]   1026 M              
NI no inhibition 
 
period of 4 weeks. From one week after surgery, zymography sup-
ported that wire injury induced a measurable increase in MMP-2 
and MMP-9 activity, which was highest at 3 weeks. Retention of 3 
in injured carotid arteries was visualized at 2, 3 and 4 weeks after 
surgery (Fig. 8). Pre-blocking of binding in mice resulted in a sub-
stantial reduction in retention of 3. Blocking of sections of left-
carotid arteries at 3 weeks after surgery with the broad spectrum 
MMPI 1,10-phenanthroline (10 mmol/L) significantly inhibited 
binding of 3. Finally, an excellent correlation was obtained between 
uptake of 3 and weekly variations in the vessel wall cross-sectional 
area but not with modifications in the total vessel or luminal areas. 
 Tavakoli et al. [31] evaluated 5 in ApoE-/- mice under high fat 
diet which received left common carotid artery wire injury. Two 
weeks after surgery, mice fed high cholesterol diet with carotid 
surgery, showed significantly higher uptake in the left carotid ar-
tery, compared to sham-operated mice or right carotid artery of both 
groups. [
99m
Tc]-(HYNIC-RP805)(tricine)(TPPTS) retention was 
significantly reduced after diet withdrawal (Fig. 9). A longitudinal 
study showed persistence of the tracer uptake in the left carotid in 
high fat diet mice after two and four weeks of surgery. Removal of 
the high fat diet resulted in a significant decrease of retention of 5 
in the left carotid. Significant decrease in MMP-2, -3, and -13 ex-
pression levels in injured arteries was obtained in mice with high fat 
diet withdrawal. Only MMP-12 remained significantly elevated in 
the injured artery in the withdrawal group. Removal of the high fat 
diet led to a significant decrease in left carotid neointima formation 
compared to high fat diet mice. Finally, high fat diet animals 
showed a significant increase in monocyte/macrophage infiltration 
in contrast to sham-operated mice. 
 Sahul et al. [32] analysed pigs, which underwent MI, with MRI 
and SPECT/CT imaging with 5. The left ventricular (LV) end dia-
stolic volumes were significantly higher at each time point com-
pared to control pigs. Pigs at 1, 2 and 4 weeks after surgery showed 
retention of 5 in the posterolateral wall, with a maximal uptake at 2 
weeks post-MI. Ex vivo imaging of LV slices substantially corre-
lated with the in vivo accumulation of 5 in the region of perfusion 
defect even if some tracer uptake was also obtained in remote re-
gions 1 and 2 weeks after surgery. An increase in uptake of 5 was 
obtained in all myocardial regions after 1 and 2 weeks MI surgery, 
with 4 times higher retention in the infarct region compared to con-
trols. Pigs at 4 weeks post-MI had similar uptake of 5 in the remote 
area than control pigs but showed higher accumulation in the infarct 
and border regions compared to controls. Zymography demon-






















Fig. (9). Fused microSPECT/CT images of mice, administered with 5, 2 
weeks after left common carotid artery wire injury with a high fat diet or 
diet withdrawal. 
 
and different areas of myocardial segments; in addition an exponen-
tial correlation between the post MI-change in LV end diastolic 
volume and MMP activity was found by using a specific global 
MMP fluorogenic substrate. Ex vivo MMP-2 activity showed the 
best correlation with regional uptake of 5. 
Atherosclerotic Lesions Imaging  
 Fujimoto et al. [33] tested 5 in rabbits with atherosclerotic le-
sions with SPECT/CT. Control rabbits did not show any accumula-
tion of the tracer. 5 was clearly visualized in atherosclerotic lesions. 
In blocking experiments, [
99m
Tc]-(HYNIC-RP805)(tricine)(TPPTS) 
uptake in atherosclerotic lesions was reduced in a dose-dependent 
manner. The tracer uptake was also significantly reduced after diet 
withdrawal and fluvastatin treatment (cholesterol-lowering drug) 
(1.0 mg/kg). Ex vivo gamma imaging studies of harvested aortas 
Probes for Non-invasive Matrix Metalloproteinase-targeted Current Pharmaceutical Design, 2013, Vol. 19, No. 00    9 
confirmed the in vivo SPECT/CT imaging (Fig. 10). In addition, the 
retention of 5 was correlated with immunohistochemistry of macro-
















Fig. (10). Ex vivo images of explanted aortas of (1) HC diet, (2) fluvastatin 
treatment, (3) diet withdrawal and (4) control animals administered with 5. 
 
 Ohshima et al. [34] investigated 5 in mice deficient in apolipo-
protein E (apoE-/-), mice deficient in low-density-lipoprotein recep-
tor (LDLR-/-) and in control mice. Half of the apoE-/- mice and 
half of the LDLR-/- mice received a high-cholesterol diet. 5 showed 
the highest uptake in atherosclerotic lesions in apoE-/- mice with a 
high-cholesterol diet, followed by LDLR-/- mice with high-
cholesterol diet, apoE-/- mice fed with a normal chow and LDLR-/- 
mice with normal chow. Control mice presented the lowest reten-
tion (Fig. 11). Immunohistochemistry with the fluorescent staining 
of MMP-2, MMP-9 and macrophages correlated significantly with 
the uptake of 5. 
 Ohshima et al. [35] evaluated the effect of fluvastatin and mi-
nocycline (an antimicrobial agent which exhibits significant MMP 
inhibitory activity) either separately or in combination in rabbits 
with atherosclerotic lesions injected with 5. Highest retention of 5 
was observed in unmanipulated rabbits. A significant decrease was 
observed in the fluvastatin (1.0 mg/kg), high dose of minocycline 
(3.0 mg/kg) and a combination of low-dose minocycline (1.5 
mg/kg) and fluvastatin. 5 was not significantly decreased in the low 
dose minocycline group. No synergistic effect was obtained for the 
combination of low-dose minocycline and fluvastatin. The tracer 
uptake was significantly correlated with MMP-2 and MMP-9 stain-
ing.  
 Razavian et al. [36] tested 3 in atherosclerotic mouse aorta after 
dietary modification. Retention of 3 was significantly higher in the 
aorta than in the inferior vena cava (IVC) in vivo, with the highest 
accumulation in the proximal aorta. In vivo and ex vivo quantifica-
tion of 3 in the aorta resulted in a significant correlation. Oil red O 
staining of explanted areas showed a satisfactory concordance be-
tween atherosclerosis area and retention of 3; even if zones of di-
vergence were found. Mice from one month to three months high 
fat diet presented a progressive increase of [
111
In]-DTPA-RP782 
uptake along the aorta. Heterogeneity of 3 along the aorta increased 
over time. Pre-treatment with a 50-fold excess of nonlabeled pre-
cursor led to a significant reduction in tracer accumulation in the 
aorta. Oil red O staining showed that getting back to normal chow 
after two months of high fat diet resulted in about 30% reduction in 
the relative plaque area. A substantial and much more pronounced 
decrease in tracer uptake was obtained in the withdrawal group. A 
significant correlation was found between expression of MMP-2, -
3, -12 and -13 with uptake of 3 in vivo. However, MMP-9 did not 
show any substantial concordance. Dietary modification resulted in 
a significant decrease in MMP-2, -3, -12 and -13 (not MMP-9) in 
the proximal aorta. RT-PCR in aortae showed that even if a signifi-
cant correlation was obtained between CD31 (endothelial cells) or 
SM -actin (vascular smooth muscle cells) expression and uptake 
of 3; CD68 and EMR-1 expression (reflecting the presence of 
macrophages) was substantially correlated with tracer retention. 
Dietary modification did not affect CD31 and SM -actin expres-
sion however it significantly decreased aortic CD68 and EMR-1 
expression. 
 Haider et al. [37] examined the relation between apoptosis and 
MMP release in a model of atherosclerosis in rabbits. Dual radionu-
clide imaging was performed with 5 and [
111
In]-labeled annexin A5 
(AA5) (Fig. 12). The retention of 5 and AA5 was substantially 
higher in rabbits fed a high cholesterol diet than in controls. 5 and 
AA5 uptake decreased significantly in rabbits after fluvastatin 
treatment (1.0 mg/kg) and diet withdrawal. MMP-9, macrophages, 
TUNEL (terminal deoxyribonucleotide transferase-mediated nick-
end labeling) staining were significantly correlated with 5 and AA5 
uptake. In addition, culture medium apoptotic THP-1 monocytes 
confirmed MMP-9 release which suggests that apoptosis and MMP 
are interconnected in atherosclerotic lesions. 
 As MMP expression and apoptosis are both involved in early 












Fig. (11). In vivo microSPECT/CT transverse (A) and sagital (B) images of the five groups of animals 
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Annexin V)(tricine)2 were tested to characterize more advanced 
atherosclerotic disease in apoE-/- mice [38]. In the youngest group 
of apoE-/- mice, neither 5 nor [
99m
Tc]-(HYNIC-Annexin 
V)(tricine)2 accumulated in the chest or neck and showed minimal 
lesion (Fig. 13). In aortic lesions, at 20 weeks, retention of [
99m
Tc]-
(HYNIC-Annexin V)(tricine)2 was slightly higher than 5 and at 40 
weeks 5 showed significantly higher uptake than annexin V 20 and 
40 week-old mice showed significantly higher uptake of 5 com-
pared to [
99m
Tc]-(HYNIC-Annexin V)(tricine)2 in carotid. A sub-
stantial correlation was found between %ID/g of Annexin V with % 
macrophages and caspase-3 positive cells. %ID/g of 5 showed also 
a significant relationship with % macrophages and with MMP-2 
and -9 positive cells. No ex vivo correlation was possible due to the 
low number of animals. To conclude: 5 allowed to identify more 




Aneurysm Imaging  
 Razavian et al. [39] evaluated 3 and 5 in murine carotid aneu-
rysm. Arterial aneurysm was obtained by exposing the left common 
carotid artery of apoE-/- mice fed HC chow since 1 week to CaCl2. 
The right carotid artery was exposed to saline and was used as a 
control. Mice were scanned with 3 2, 4 or 8 weeks after surgery. A 
longitudinal study was performed at 2 and 4 weeks after surgery 
with 5. 3 accumulated higher at 4 weeks after surgery (Fig. 14) and 
a significantly higher uptake was obtained at each time point stud-
ied in the aneurismal left carotid than in the control. Moreover the 
uptake of 3 was significantly correlated with MMP-2 and MMP-9 
activity evaluated by zymography. Administration of a 50-fold 
excess of non-labelled precursor 15 minutes before 3 led to a sig-
nificantly decreased uptake of 3 in the left carotid which was con-
firmed by autoradiography. Addition of 1,10-phenanthroline re-
duced substantially ex vivo binding of 3 in carotid aneurysm. Longi-
tudinal study with 5 resulted in no significant correlation between 
retention of 5 and aneurysm size at 4 weeks; however the accumu-
lation of 5 at 2 weeks substantially correlated with aneurysm size at 
4 weeks. Although 5 gave a better quality image than 3, no quanti-
tative difference between both tracers was observed.  
 [
111
In]-RP782 3 and [
99m
Tc]-(HYNIC-RP805)(tricine)(TPPTS) 
5 have been rather well-characterized in vascular remodeling, athe-
rosclerotic lesions and aneurysm. The observed target-to-nontarget 
ratios were acceptable for preclinical imaging. However, 3 and 5 
were not tested in any tumor models, nor in models of inflammation 
such as asthma, COPD or rheumatoid arthritis. 
Marimastat, 6a; Marimastat-FITC, 6b; Marimastat-ArB[
18
F]F3, 
6c; and control-ArBF3 lacking the Marimastat moiety 6d 
  Keller et al. [40]; [41] tested two modified versions of the drug 
Marimastat ((2S,3R)-N4-[(1S)-2,2-dimethyl-1-[(methylamino) 
carbonyl]propyl]-N1,2-dihydroxy-3-(2-methylpropyl)butanedia-
mide) 6a (Fig. 6) in a cancer model. 6a was transformed by addi-
tion of a linker in the S3’ pocket which was either coupled with 
fluorescein isothiocyanate (FITC) leading to Marimastat-FITC 6b 
(Fig. 6) or with an aryl boronic ester for one-step [
18
F]-aqueous 
fluoride capture leading to Marimastat-ArB[
18
F]F3 6c (Fig. 6). 
67NR/CMV-luciferase murine mammary carcinoma xenograft 
mouse model was used for in vivo evaluation. Transcription of 
MMP-7, -13, -14 and -24 was significantly higher in controls than 
in tumors whereas MMP-2, -15, -23, -25 and -27 expression was 
higher in tumors compared to controls. 6a, 6b and Marimastat-
ArBF3 6c were tested in in vitro fluorogenic assays against MMP-2. 
They exhibited all IC50 in the low nanomolar range (Table 3). 
Comparable studies of murine tissue lysates with 6b indicated 
higher MMP activity in the tumors than in control mammary gland 
tissue. 6b was tested in MDA-MB-231 cells transfected with human 
MMP-14 or empty vector followed by staining. Uptake of 6b corre-
lated with MMP-14 in MDA-MB-231 cells transfected with human 
MMP-14. The design of the in vivo experiment was the following: 
after 25 days of inoculation, a bioluminescent scan was performed 
which was followed the day after either by a PET scan with 6c or 
control-ArBF3 lacking the Marimastat moiety 6d (Fig. 6). Specific-
ity of 6c was tested with injection of 300 nM 6a (>10-fold excess of 
6a) 1 hour before tracer administration. Tumors were imaged by 
luciferase bioluminescence. The uptake of 6c was low but detect-















Fig. (12). Example of microSPECT and fused microSPECT/CT images of atherosclerotic rabbits under HC diet injected with 5 or AA5. 








































Fig. (13). In vivo antero-posterior images of apoE-/- mice injected with AA5 
or 5 at three different time points. 
 
not allow visualizing the tumor. The time activity curve indicated 
that a plateau level of radioactivity is reached in the tumor after 60 
min. Blocking prior to tracer injection led to a decrease in retention 
of 6c in the tumor (Fig. 15). To conclude, Marimastat was success-
fully radiolabelled with a novel [
18
F]-radiolabelling procedure in a 
low RCY. The newly obtained tracer Marimastat-ArB[
18
F]F3 al-
lowed specific visualization of 67NR tumor with a relatively low 
signal to noise ratio.  
Nonpeptidomimetic Sulfonamide Hydroxamates 
 Nonpeptidomimetic MMPIs were designed based on the three-
dimensional structure of the MMP active site. These inhibitors, 










Fig. (14). Example of fused microSPECT/CT images of a mouse, 4 weeks 
























                   Unblocked                                               Blocked  
 
Fig. (15). In vivo microPET images of 67NR breast tumor mice injected 
with 6c (left panel) and in a pre-blocked mouse (right panel) [40]. 
 
which affords hydrogen bonding with the enzymes. Because of 
their structure-based design, these compounds exhibit greater speci-
ficity than peptidomimetic compounds [13]. 






 Oltenfreiter et al. [42]; [43] synthesized the SPECT-tracer 7 
(Fig. 16) by electrophilic aromatic substitution of the tributylstannyl 
derivative. In vitro fluorogenic assays were performed on the 
bromo and iodo inhibitors against pro-MMP-2, pro-MMP-9, the 
recombinant catalytic domain of MT1-MMP (cMT1) and MT3-
MMP (cMT3). The bromo analog shows nanomolar affinities in 
vitro against pro-MMP-2, pro-MMP-9, cMT1 and cMT3 (Table 3). 
Inhibition values of the iodo inhibitor against pro-MMP-2, pro-
MMP-9, cMT1 and cMT3 are also in the nanomolar range (Table 
3). This radioiodinated tracer was evaluated in mice bearing A549 
lung tumors. Tumor %ID/g was 0.72 ± 0.29 3 hr p.i. and 0.07 ± 
0.04 48 hr p.i; the tumors were not visualised at both time points. A 
tumor/blood ratio of 1.20 and a tumor/muscle ratio of 3.21 were 
obtained 48 hr p.i. The blood exhibited 66.2% of intact tracer 
whereas the tumor showed 87.8% of intact activity 2 hr p.i. How-
ever, metabolism and strong uptake in liver/intestines suggests that 





 Oltenfreiter et al. [44]; [45] prepared the analogue 8 of the pre-
vious SPECT-tracer 7 (Fig. 16) by adding an isopropyl group 







































 R1 A X Y B C R2 
9 H H CH CH H H O11CH3 
10 
11CH3 H CH CH H H OMe 
11 H H N.HCl          CH H H OMe 
12a H H CH CH H H OCH2CH2
18F 
12b H H CH CH H H 18F 
13a 
11CH3 H N CH H H OMe 
13b 
11CH3 H CH N H H OMe 
13c 
11CH3 H N CH NO2 H H 
13d 
11CH3 H N CH H NO2 H 
13e 
11CH3 H N CH H H NO2 
14a 
11CH3 H N CH F H H 
14b 
11CH3 H N CH H H F 
14c 
11CH3 H N CH Cl H H 
14d 
11CH3 H N CH H Cl H 
14e 
11CH3 H N CH H H Cl 
14f 
11CH3 H N CH Br H H 
14g 
11CH3 H N CH H Br H 
14h 
11CH3 H N CH H H Br 
14i 
11CH3 H N CH H H I 
15a H H N CH H I OH 
15b H H N CH H 123I OH 
15c H H N CH H 125I OH 
15d H H N CH H H I 
15e H H N CH H H 123I 
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15f H H N CH H H 125I 
16 H H N CH H H OCH2CH2
18F 
17 H 18F N CH H H OMe 
















Fig. (16). Structure of nonpeptidomimetic sulfonamide hydroxamate-based MMP inhibitors for PET/SPECT. 
 
instead of a 1H-indol group at the alpha carbon of the hydroxamic 
acid. The iodo inhibitor was tested in in vitro fluorogenic assays 
against cMT1, cMT3, pro-MMP-2 and pro-MMP-9 (Table 3). The 




 M affinities against pro-MMP-2, 
pro-MMP-9, cMT1 and cMT3. This radioiodinated tracer was 
tested on an A549 adenocarcinoma xenograft mouse model. Tu-
mors were slightly visualised in the scan and a low tumor uptake 
was obtained: 0.71 ± 0.08 ID/g 3 hr p.i. and 0.17 ± 0.08 ID/g 48 hr 
p.i. At 48 hr p.i., a tumor/blood ratio of 1.04 and a tumor/muscle 
ratio of 1.57 were obtained. Two third of intact tracer and one me-
tabolite were found in the plasma whereas the tumor showed ap-
proximately 90% of intact tracer 2 hr p.i. Additional studies are 
necessary to show the specificity of the binding of 8. 









C]CGS 25966, 9 
 Fei et al. [46] synthesized 9 (Fig. 16) by selective methylation 
of the phenol-hydroxyl group with [
11
C]-methyl triflate. Inhibition 
values against MMP-1, -2, -3, -8, -9 and -12 were in the nanomolar 
range (Table 3). 
 Zheng et al. [47] evaluated 9 in mice bearing MCF-7 (trans-
fected with IL-1a) or MDA-MB-435 tumors (models of human 
breast cancer metastasis, which express MMP activity). At 45 min-
utes p.i., the %ID/g, tumor/ blood and tumor/ muscle ratios were 
respectively 0.42, 1.09 and 0.84 for MCF-7/IL-1a and 1.53, 1.27 
and 1.95 for MDA-MB-435 tumors. Tumors were not visible in 
either of the tumor models, which suggest that 9 is not a suitable 
PET tracer for cancer imaging.  
[
11
C]-Methyl-benzyl-CGS 25966, 10 
 Fei et al. [48] performed [
11
C]-methylation of CGS 25966 at the 
aminohydroxyl position leading to the lipophilic inhibitor 10 (Fig. 
16). As the ZBG of O-methylated hydroxamic acid has an identical 
role as the ZBG of hydroxamic acid, the structural modification of 
CGS 25966 to methylated CGS 25966 10 was supposed not to alter 
its inhibitory property. A fibril degradation assay with fluorogenic 
substrates specific for MMP-1 was performed with 10 and CGS 
27023A 11 (N-hydroxy-2(R)-[[(4- methoxyphenyl)sulfonyl](3-
picolyl)-amino]-3-methyl-butanamide) (Fig. 16); [49]. 11 has a 
similar structure as CGS 25966 except the N-substituent was re-
placed by a picolyl group. 11 is a potent MMP inhibitor for several 
MMP subtypes [46]; (Table 3). Thus, the fibril degradation assay 
demonstrated that the modified compound 10 showed strong inhibi-
tory effectiveness against MMP-1, compared to 11.  
[
18
F]-fluoroethoxy-CGS 25966 - [
18
F]-BR351, 12a 
 A fluorinated MMP inhibitor 12a (called [
18
F]-BR351) (Fig. 
16) based on the broad-spectrum inhibitor CGS 25966 was prepared 
by Wagner et al. [50]; [51]. A fluorogenic assay on the reference 
compound was performed. Measured inhibition constants are in the 
nanomolar range for MMP-2, -8, -9 and -13 (Table 3). [
18
F]-
fluoroethoxy-CGS 25966 12a was tested in wild-type (WT) mice. 
Ex vivo analysis showed no tissue specific accumulation of 12a. 
Blocking with unlabelled 12a (10 min previous tracer injection) did 
not exhibit a significant effect on the biodistribution and clearance, 
thus no specific binding of 12a to MMPs was observed in any tis-
sues. Studies in cancer, inflammation, or atherosclerosis models 
have not yet been performed.  
 Toxicological tests [52] of the reference compound 12a in rats 
were performed and no toxicity was observed when [
19
F]-12a was 
administered at the mg/kg-range to rats.  
Picolyl-benzenesulfonamide Hydroxamate-based MMP Inhibitors 
[
11





C]-methyl-2-nitro-CGS 27023A, 13c; [
11
C]-
methyl-3-nitro-CGS 27023A, 13d; and [
11
C]-methyl-4-nitro-CGS 
27023A, 13e  
 Fei et al. [48] prepared five analogs of CGS 27023A 11: [
11
C]-





C]-methyl-2-nitro-CGS 27023A 13c, [
11
C]-methyl-3-nitro-
CGS 27023A 13d and [
11
C]-methyl-4-nitro-CGS 27023A 13e (Fig. 
16). Those five inhibitors were also tested in a fibril degradation 
assay against active MMP-1. It demonstrated substantial inhibitory 
effectiveness of these inhibitors similar to 11, although the nitro-
inhibitors displayed a slightly reduced inhibitory potency. 
[
11
C]Me-2-F-CGS 27023A, 14a; [
11
C]Me-4-F-CGS 27023A, 14b; 
[
11
C]Me-2-Cl-CGS 27023A, 14c; [
11
C]Me-3-Cl-CGS 27023A, 14d; 
[
11
C]Me-4-Cl-CGS 27023A, 14e; [
11
C]Me-2-Br-CGS 27023A, 14f; 
[
11





C]Me-4-I-CGS 27023A, 14i  





C]Me-2-F-CGS 27023A 14a, [
11
C]Me-4-F-
CGS 27023A 14b, [
11
C]Me-2-Cl-CGS 27023A 14c, [
11
C]Me-3-Cl-
CGS 27023A 14d, [
11
C]Me-4-Cl-CGS 27023A 14e, [
11
C]Me-2-Br-
CGS 27023A 14f, [
11
C]Me-3-Br-CGS 27023A 14g, [
11
C]Me-4-Br-
CGS 27023A 14h and [
11
C]Me-4-I-CGS 27023A 14i (Fig. 16). A 
fibril degradation assay with fluorogenic substrates specific to 
MMP-1 was performed with the reference compounds of these 
inhibitors 14a-i and 9. This library of inhibitors showed significant 
inhibitory effectiveness against MMP-1, similar to the parent com-
pound CGS 27023A. No in vivo evaluation was performed. 
[I]I-HO-CGS 27023A, 15a; [
123
I]I-HO-CGS 27023A, 15b; [
125
I]I-
HO-CGS 27023A, 15c; [I]I-CGS 27023A, 15d; [
123
I]I-CGS 
27023A, 15e; and [
125
I]I-CGS 27023A, 15f 
 Kopka et al. [54] modified and radiolabelled CGS 27023A 
resulting in six iodo derivatives of 12: I-HO-CGS 27023A 15a, 
[
123
I]I-HO-CGS 27023A 15b, [
125
I]I-HO-CGS 27023A 15c, I-CGS  
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Fig. (17). Structure of carboxylate-based MMP inhibitors for PET/SPECT. 
27023A 15d, [
123
I]I-CGS 27023A 15e and [
125
I]I-CGS 27023A 15f 
(Fig. 16). In vitro studies indicated that 15d has similar inhibitory 
potency as its parent compound 12 on the other hand 15a showed 
decreased inhibitory effectiveness compared to 12 (Table 3) which 
is probably due to the strain of the polar hydroxyl group for entry 
into the hydrophobic S1’ pocket supplemented by the steric hin-
drance of the bulky ortho iodine. An in vivo biodistribution study 
using 15c in wild-type mice showed rapid blood and plasma clear-
ance and low retention in normal tissues. 
 Schäfers et al. [55] evaluated 15e four weeks after left carotid 
ligation and cholesterol-rich diet in apoE-/- mice, WT mice and 
sham-operated controls. [
123
I]I-HO-CGS 27023A accumulated pro-
gressively in the left carotid lesion of apoE-/- mice whereas neither 
carotid-ligated wild-type mice nor sham-operated apoE-/- mice 
exhibited any specific retention of 15e in the region of interest. 
ApoE-/- mice with surgery have approximately 1.5 fold increase of 
15e in the left carotid ligation compared to apoE-/- mice injected 
with 1.2 mol of CGS 27023A 2 hours before the scan. As vascular 
(carotid lesion) and paravascular accumulation of the radioligand 
can not be distinguished by planar scintigraphy, ex vivo analysis 
was performed to confirm the specificity of the binding. A 2.72-
fold higher uptake in the left-carotid artery compared to the right-
carotid artery was achieved. Moreover, after administration of 1.2 
mol of CGS 27023A, the uptake in left carotid artery was signifi-
cantly reduced compared to the untreated left carotid artery (ap-
proximately 10 times) and no difference in the right-carotid artery 
between unblocked and blocked ApoE-/- mice was observed. Fi-
nally, microautoradiography with [
125
I]I-HO-CGS 27023A 15e was 
performed in order to prove that binding of 15e coincided with 
lesions that were rich in MMP activity. The autoradiographic signal 
in the carotid lesion matched with areas that were high in MMP-9 
activity, confirmed by immunostaining. 15e allowed detecting spe-
cifically MMP activity in vivo in the MMP-rich vascular lesions 
developed after carotid artery ligation and cholesterol-rich diet in 
apolipoprotein E-deficient mice. 
[
18
F]-fluoroethoxy-CGS 27023A, 16  
 Breyholz et al. [51]; [56] performed fluoroalkylation of the 
phenolic hydroxyl group of CGS 27023A in order to produce [
18
F]-
fluoroethoxy-CGS 27023A 16 (Fig. 16). Fluorogenic in vitro assays 
showed nanomolar affinities of [
19
F]fluoroethoxy-CGS 27023A 
against MMP-2, -8, -9 and -13 (Table 3). [
18
F]fluoroethoxy-CGS 







 Wagner et al. [50]; [57] synthesized 17 (Fig. 16), a fluorinated 
analog of CGS 27023A, by nucleophilic aromatic substitution of 
the corresponding bromide-precursor in one-step. 17 exhibited in-
hibitory potency in the low nanomolar range for MMP-2, -8, -9 and 
-13 (Table 3). Only a preliminary in vivo study in wild-type mice 




MMP inhibitors and N-triazole-benzenesulfonamide hydrox-




methoxyphenylsulfonamido)-N- hydroxy-3-methylbutanamide, 18 
 Hugenberg et al. [58] synthesized eight [
19
F]-fluorinated tria-
zole-substituted hydroxamate MMPIs and radiolabelled one of them 
18 (Fig. 16). Fluorogenic inhibition assay of 18 against MMP-2, -8, 
-9 and -13 resulted in picomolar affinities (Table 3). The hydro-
philic triazole nitrogen atoms could potentially give additional in-
teractions with the Zn
2+
 ion or other functional groups of the en-
zyme backbone. 18 exhibited excellent stability in human and 
mouse serum up to 120 min. 18 was tested in C57/Bl6 mice and did 
not exhibit any tracer specific accumulation. This MMPI was 
cleared rapidly and efficiently from the body through hepatic and 
Probes for Non-invasive Matrix Metalloproteinase-targeted Current Pharmaceutical Design, 2013, Vol. 19, No. 00    15 
renal elimination. 18 was not tested in any animal model of pa-
thologies. 
2.2.2. Carboxylate-based MMP Inhibitors 
 Considering the importance of a ZBG for MMP inhibitors, 
compounds with other ZBGs have attracted large interest. The sec-
ond most popular ZBG is the carboxylic acid moiety which inter-
acts by mono-complexation with the zinc active site. It has been 
established that hydroxamate binding has a 3.5 kcal/mol advantage 
over carboxylate. The lower affinity is however counterbalanced by 
a superior metabolic stability [17]. 






methylbutyric acid) - [
11
C]MSMA, 19 
 Zheng et al. [47] prepared [
11
C]MSMA 19 (Fig. 17) in a two 
step procedure by [
11
C]-O-methylation of the benzyl ether precursor 
followed by a quick hydrolysis of the tert-butyl ester. MSMA 
showed nanomolar affinities for MMP-2, -3 and -13 and micromo-
lar affinities for MMP-1, -7 and -9 (Table 3). [
11
C]MSMA was 
tested in mice bearing breast cancer MCF-7 (transfected with IL-1a) 
or MDA-MB-435 tumors. At 45 minutes p.i., the %ID/g, tu-
mor/blood and tumor/muscle ratios were 0.95, 0.99 and 1.21 for 
MCF-7/IL-1a xenograft and 0.98, 1.27 and 1.38 for MDA-MB-435 
xenograft. None of the tumors were visible in a microPET scan, 


























ester, 20d, 20e, 20f; and (S)-3-methyl-2-(4’-nitrobiphenyl-4-
sulfonylamino)butyric acid [
11
C]methyl ester, 20 g  
 Fei et al. [59] synthesized a series of seven MMP inhibitors by 
[
11




C]methyl ester, 20a, (S)-3-methyl-2-(3’-methoxybiphenyl-4-sul-
fonylamino)butyric acid [
11







C]methyl ester, 20d, (S)-3-methyl-2-(3’-fluorobiphenyl-4-
sulfonylamino)butyric acid [
11




20f, and (S)-3-methyl-2-(4’-nitrobiphenyl-4-sulfonylamino)butyric 
acid [
11
C]methyl ester 20g (Fig. 17). The corresponding carboxylic 
acids of 20c, 20f and 20g are 21a, 21b and 21c (Fig. 17). The refer-
ence compounds of 20a-g and 21a-c were tested in a fibril degrada-
tion assay with fluorogenic substrates specific for active MMP-13. 
This library of inhibitors showed significant inhibitory effectiveness 
against MMP-13. Fei et al. preferred to make the [
11
C]-labeled 
methyl ester prodrug (neutral) rather than the [
11
C]-labeled acid 
drug (positively charged at physiological pH) because of the easier 
synthesis of the methyl ester prodrug compared to the parent car-
boxylic acid drug. Furthermore, the methyl ester is equivalent to 
carboxylic acid in binding zinc in SAR study [11]. None of the 




amino]benzenesulfonyl]amino] butanoic acid, 22 
 Kuhnast et al. [60] prepared (2R)-3-methyl-2-[[4-[(4-
[
11
C]methoxybenzoyl)amino]benzenesulfonyl] amino]butanoic acid 
22 (Fig. 17) by methylation of the phenol precursor. An in vitro 
gelatin degradation assay on the reference compound was per-
formed and sub-micromolar IC50 values were obtained (Table 3). 
Biodistribution and in vivo serum stability tests in normal mice 
were carried out. 22 showed rapid excretion within the first 30 min 
after injection. In addition, 2 exhibited stability towards degradation 










propionic acid 23 (Fig. 17). The corresponding bromo and iodo 
inhibitors were tested in in vitro fluorogenic assays against recom-
binant pro-MMP-2, pro-MMP-9, cMT1 and cMT3. They exhibited 




 M range for the bromo-inhibitor and the 
iodo-inhibitor (Table 3). 23 was evaluated in mice bearing A549 
lung tumors. Tumor ID/g were 0.27 ± 0.10 at 3 hr p.i. and 0.04 ± 
0.05 at 48 hr p.i. but the tumors were not visualised at both time 
points. A tumor/blood ratio of 3.09 and a tumor/muscle ratio of 0.8 
were obtained 48 hr p.i. 5% of intact tracer was found in the blood 
while the tumor exhibited 75.9% of intact activity at 2 hr p.i. The 
rather negative outcome of this study (low tumor uptake, high me-
tabolism, high uptake in liver/intestines) suggests that 23 is not a 















ties against pro-MMP-2, pro-MMP-9, cMT1 and cMT3 (Table 3). 
24 was tested in a A549 xenograft mouse model. A low tumor up-
take was found, tumors were faintly visualised in the scan (Fig. 18). 
Tumor uptake was 2.00 ± 0.40 ID/g at 3 hr p.i. and 0.75 ± 0.44 ID/g 
at 48 hr p.i. A tumor/blood ratio of 0.52 and a tumor/muscle ratio of 
4.63 were obtained at 48 hr p.i. Metabolite analysis showed hardly 
any degradation of 24 at 2h p.i. Image quality was improved by 
decreasing the specific activity of 24 leading to a lower liver uptake 
due to saturable binding in the liver. Further analysis is required to 
prove the specificity of the binding of 24.  
Phenylsulfonamide carboxylate-based MMP inhibitors with a 




methylbutyric acid - [
18
F]SAV03, 25a 
 Furumoto et al. [61] prepared 25a (called [
18
F]SAV03) (Fig. 
17) in one-pot synthesis by radiofluorination of the tosyl precursor 
followed by hydrolysis of the methyl ester. The reference com-
pound showed micromolar affinity against MMP-2 (Table 3). A 
biodistribution study of 25a using Ehrlich tumor bearing mice 
showed that uptake in tumor was higher than in other organs, ex-
cept for the liver, small intestine and bone with %ID/g of 0.52 ± 
0.16 at 30 min and 0.22 ± 0.07 at 120 min. Tumor/muscle and tu-
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methylbutyric acid methyl ester - [
18
F]SAV03M, 25b 
 Furumoto et al. [61] prepared also the methyl ester of 25a, 25b 
(Fig. 17) (called [
18
F]SAV03M), in the same way as 25a without 
the deprotection step. A comparative in vivo study by using 25b as 
a prodrug was performed. The uptake in the liver at 30 min p.i. 
decreased by half and that in tumor increased by 2.4 times com-
pared with 25a. The tumor/muscle ratio was also much higher 13.9 
± 4.9, 120 min p.i. Radio-thin-layer chromatographic analysis of 
25b metabolites indicated that 25b was easily converted to the par-
ent drug 25a in vivo and accumulated in tumor tissue. Specificity 
studies, such as pre-blocking mice or coinjection of unlabelled pre-
cursor, should be performed in order to check if 25b is suitable for 









  Furumoto et al. [62] prepared two [
18
F]-labeled MMP inhibi-
tors 25c and 25d (Fig. 17) by variation of the substituents in  of 




C]methyl ester - [
11
C]FMAME, 26 
 Zheng et al. [63] prepared the methyl ester prodrug 26 (Fig. 
17). The reference compound was also prepared. The parent drug 
FMA exhibited an IC50 of 1.9 M for MMP-2. This [11C]-methyl 
ester prodrug was tested in mice bearing MCF-7/IL-1a or MDA-
MB-435 tumors. Biodistribution at 30 min p.i. revealed a %ID/g, 
tumor/muscle and tumor/blood ratio of 1.13, 1.05 ± 0.29 and 0.77 ± 
0.20 for MCF-7/IL-1a tumors and 1.37, 0.99 ± 0.35 and 1.44 ± 0.69 
for MDA-MB-435 tumors. Pretreatment with 2.5 mg/kg of FMA 30 
minutes before 26 administration did not lead to significant reduc-
tion of %ID/g, tumor/muscle and tumor/blood ratios for MCF-7/IL-
1a and MDA-MB-435 tumors. The tumors were visualized in the 
PET scan but tracer binding was non-specific suggesting that 26 is a 
not a suitable PET-tracer for tumor imaging.  
2.2.3. Barbiturate-based MMP Inhibitors 
 Besides hydroxamates and carboxylates, another ZBG was 
tested for molecular imaging of metalloproteinase expression: 
pyrimidine-2,4,6-trione also named barbiturate. This novel ZBG 
(Fig. 19); [64] required a cyclic urea which coordinates the zinc 
monodentately via its carbonyl. One of the N-H groups from the 
urea is necessary for hydrogen bonding with Gly amide carbonyl 
and the other N-H required a low pKa for hydrogen bonding to glu-
tamate base. In addition, a linker which conformationally makes a 
U-turn between the ZBG and the P1’ pocket is necessary. The 
linker must have an H-bond acceptor for interaction with Gly and 






 Breyholz et al. [65] prepared a series of C-5-disubstituted barbi-
turate MMP inhibitors from which they only labelled one inhibitor 
with [
125
I]NaI from the bromo-precursor to obtain 27 (Fig. 20). 
MMP-2 and MMP-9 fluorogenic assays on the nonradioactive ref-
erence compound were performed and low nanomolar values were 






 Breyholz et al. [66] radiosynthesized a [
18
F]-fluoroethyl radio-
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Fig. (20). Structure of barbiturate-based MMP inhibitors for PET/SPECT. 
 
in wild-type mice and preliminary biodistribution studies showed 







  Schrigten et al. [67] prepared a library of barbituric acid-based 
MMP inhibitors of the second generation (less lipophilic). 29 (Fig. 
20) was radiolabelled in a two-step procedure by fluorination of the 
tosyl-ethylazide followed by copper(I) catalyzed 1,3-dipolar cy-
cloaddition. Fluorogenic inhibition assay of 29 against MMP-2, -8, 
-9 and -13 resulted in nanomolar affinities (Table 3). In vitro stabil-
ity of this tracer in human serum for up to 120 min at 37°C was 
excellent. In vivo evaluation in WT mice demonstrated no tissue 
specific retention of 29 with a more rapid clearance behaviour of 29 








 Claesener et al. [68] prepared the PET-tracer 30 (Fig. 20) by 
copper-free cycloaddition of an azido moiety linked to the inhibitor 
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backbone and a cyclooctyne-DOTA derivative. 30 was radiola-
belled with 
68
Ga and was radiosynthesized in two manners, either 
by a pre-labelling approach or a post-labelling one. The azido-
precursor showed nanomolar affinities for the gelatinases: 24 nM 
for MMP-2 and 68 nM for MMP-9. No in vitro or in vivo studies 
were performed on 30. 
2.3. MMP Peptides  
 Peptides [69] were also developed as probes for non-invasive 
detection of MMP expression. Koivunen et al. prepared a specific 
gelatinase inhibitor from phage display peptide library: 
CTTHWGFTLC (Cys-Thr-Thr-His-Trp-Gly-Phe-Thr-Leu-Cys) 31 
(abbreviated CTT) (Fig. 21). This cyclic decapeptide, which con-
tains the motif HWGF, inhibited only gelatinases (IC50 (MMP-2) = 
10 M, IC50 (MMP-9) < 10 M) whereas no inhibition was ob-
tained for MMP-8, -13 and -14. Even if the inhibitory mechanism 
of this peptide is still unclear, the tryptophan residue fits probably 
the S1’pocket whereas the histidine residue could act as a ligand for 
the catalytic zinc ion. The cyclic conformation is essential for the 
activity of the peptide. CTTHWGFTLC was found to inhibit the 
migration of human endothelial cells and tumor cells. It also 





 Kuhnast et al. [70] modified the N-terminal of 31 with a D-
tyrosine and labeled the resulting peptide with [
125
I]NaI in order to 
obtain [
125
I]-yCTTHWGFTLC 32 (Fig. 21). yCTTHWGFTLC in-
hibited MMP-2 in the range of 5 to 10 M and the IC50 of MMP-9 
was more than 10-fold lower (Table 3). Derivatisation of CTT did 
not affect its inhibitory properties towards gelatinases. After 60 min 
of incubation with the purified activated enzymes MMP-2 and 
MMP-9, the entire radioactivity was recovered as the intact tracer. 
32 was tested in Lewis Lung cancer tumor bearing mice. Excretion 
organs (liver, kidneys and intestines) show high uptake and a mod-
erate accumulation of 32 was obtained in the tumor. The tu-
mor/muscle ratio was 2.56 at 2 hrs after injection. Metabolite analy-
sis of the serum collected 10 min after injection indicated 75% of 
intact tracer with two metabolites, one of which is 3-[
125
I]iodo-D-
tyrosine. Coinjection of 12 mg/kg of unlabelled peptide with 32 led 
to a significant decrease (37%) in tumor uptake, however treatment 
with yCTTHWGFTLC did not substantially affect the concentration 
of 32 in the blood. The poor metabolic stability and the small 
amount of specific binding of 32 make it unsuitable for targeting of 
gelatinases in vivo.  
[
64
Cu]-DOTA-CTT, 33; and [
64
Cu]-DOTA-STT, 34 
 Sprague et al. [71] prepared a PET tracer from 31 by conjuga-
tion with the bifunctional chelator DOTA (1,4,7,10-
tetraazacyclotetradecane-N,N’,N’’,N’’’-tetraacetic acid) for radio-
labelling with 
64
Cu leading to 33 (Fig. 21).
 
The linearly scrambled 
peptide STTGHFWTLS (Ser-Thr-Thr-Gly-His-Phe-Trp-Thr-Leu-
Ser) (abbreviated STT), which was used as a negative control, was 
also radiolabelled to give [
64
Cu]-DOTA-STT 34 (Fig. 21). 33 and 
34 were tested for in vitro stability with rat serum. After 1 hr of 
incubation, both tracers did not show any degradation. From 1 to 6 
hr, more than 95% of the recovered radioactivity corresponded to 
33. Nevertheless, after 24hrs of incubation, the stability of 33 
decreased substantially with 41.7 ± 8.1% of intact tracer. Fluoro-
genic substrate assays of CTT, Cu(II)-DOTA-CTT, STT and 
Cu(II)-DOTA-STT were performed against human MMP-2 
(hMMP-2), mouse MMP-9 (mMMP-9) and human MMP-9 
(hMMP-9). Cu(II)-DOTA-CTT exhibited low micromolar affinities 
(Table 3). The conjugation of CTT to Cu(II)-DOTA did not 
substantially modify the affinity of the ligand towards the 
gelatinases. STT showed EC50 of >1000 M, 104 M and not 
determined (ND) and Cu(II)-DOTA-STT: >1000 M, 20.4 M and 
ND, respectively. STT has an affinity 10-fold lower than CTT for 
mMMP-9 however Cu(II)-DOTA-STT and Cu(II)-DOTA-CTT 
inhibited mMMP-9 in the same range. Neither STT nor Cu(II)-
DOTA-STT inhibited hMMP-2. 33 and 34 were tested in B16F10 
tumor-bearing mice. Ex vivo analysis demonstrated a 2.7-fold 
higher uptake in the tumor for 33 than 34 (2.44 ± 0.26 vs 0.91 ± 
0.10). However, [
64
Cu]-DOTA-CTT showed higher accumulation 
in every organ than [
64
Cu]-DOTA-STT. The tumor/blood ratio of 
33 and 34 was not significantly different (2.12 ± 0.70 vs 1.82 ± 
0.68). MicroPET images also exhibited a two-fold higher uptake of 
33 over 34. Zymography indicated MMP-2 and MMP-9 expression 
in B16F10 tumor extracts and to a lower extent in blood. 33 and 34 
were evaluated in a second tumor model: MDA-MB-435 tumor-
bearing mice. Zymography demonstrated that the expression of 
both gelatinases was not consistent among the evaluated tumors 
evaluated and only one out of 24 scanned mice exhibited retention 
of 34 in MDA-MB-435 tumor, which was confirmed by 
zymography. Micromolar affinities towards the gelatinases and 
poor in vivo stability indicated that [
64
Cu]-DOTA-STT is not a suit-




 Hanaoka et al. [72] attached the highly hydrophilic and nega-
tively charged [
111
In]-DTPA to 31 in order to obtain [
111
In]-DTPA-
CTT 35 (Fig. 21). 35 exhibited lower IC50 than the mother com-
pound CTT (Table 3). After 3 hrs of incubation at 37
0
C in murine 
serum, approximately 85% of the radioactivity represented intact 
tracer. 35 was tested in two xenograft mouse models: MDA-MB-
231 and MDA-MB-435S. The % ID/g in the tumor 3 hr p.i. was 
higher in MDA-MB-231 xenograft than MDA-MB-435S xenograft. 
However the gelatinase activity was significantly stronger in MDA-
MB-231 tumor than MDA-MB-435S tumor. The % ID/g in the 
tumor and the tumor-to-blood ratio demonstrated a substantial cor-












 Ujula et al. [73] evaluated a MMP-9 targeting peptide obtained 
from a phage display (by biopanning of tumor cells) and two modi-
fied versions in a C8161T/M1 melanoma xenograft rat model. All 
three peptides were conjugated with DOTA and radiolabelled with 
68
Ga to lead to 36, 37 and 38 (Fig. 21). All three PET peptides were 
stable in saline up to 4 hr. 37 did not show any degradation after 4 
hr of incubation in human plasma; however 36 and 38 exhibited 
lower stability, with a respective half-life of about 2.5 hr and 1 hr. 
The plasma protein of 36 was analyzed in vitro and resulted in 
about 35 ± 1% of the tracer complexed with plasma proteins. The 
stability of the peptides at 15 min and at 120 min p.i. was evaluated 
in vivo in a rat melanoma xenograft model in plasma, tumor and 
urine. It was shown that 37 exhibited the greatest stability in vivo, 
followed by 36, in contrast to 38 which showed a fast degradation 
in vivo. 36 and 37 allowed visualizing clearly the tumor in the PET 
scan. 37 exhibited slower uptake in the tumor than 36, however a 
longer retention in the tumor was observed due to the higher stabil-
ity of the peptide. 38 showed an overall background signal. The 
tumor/muscle ratios after 120 min of administration of 36, 37 and 
38 were respectively 5.5 ± 1.3, 3.2 ± 0.2 and 3.2 ± 0.6. 36 demon-
strated a tumor/blood ratio of 1.2 ± 0.3 120 min p.i. Ex vivo biodis-
tribution was performed on rats, after tumor growth from two to 
four weeks, administered with 36. The highest SUV and tu-
mor/muscle ratios were obtained three weeks after inoculation. 
Attempts to correlate MMP-9 levels by zymography with ex vivo 
data led to a weak correlation coefficient of 0.33. The parental 
compound 36 gave the highest retention in tumor. Even if the ac-
cumulation of 36 was low, additional studies have to be performed 
to prove its specificity. Modification of the peptide by a lactam 
bridge instead of a cystine bridge resulted in higher stability and 
should be further evaluated. 


















































































































































































































































































































































































































































































































































































































































Fig. (21). Structure of MMP peptides for PET/SPECT. 
 




 Cheng et al. [74] pepared three probes from the hydrophilic 
peptide Cys-Arg-Ser-Gly-Pro-Leu-Gly-Val-Thr-Lys-Lys (abbrevi-
ated CRSGPLGVYKK) to which was attached the hydrophobic 
fluorescent dye tetramethylrhodamine (TMR) leading to 39, 40 and 
41 (Fig. 21). 39 was cleaved by purified MMP-2 or medium from 
HT1080 cells (MMP>0) to release TMR but not from MCF-7 cells 
(control). The cleavage of 39 was blocked by 10 M 1,10-phenan-
throline which demonstrated that 39 was selectively hydrolyzed by 
MMP-2 and MMP-expressing cells. 40 was evaluated in vitro with 
HT1080 cells or MCF-7 cells cultured 48h in serum-free medium. 
HT1080 cells exhibited strong fluorescence contrary to MCF-7 
cells. Addition of MMP-2 to MCF-7 cells led to a retention of fluo-
rescence at the MCF-7 cells. Treatment of HT1080 cells with 10 
M 1,10-phenanthroline resulted in a substantial 10-fold lower 
fluorescent signal. Both TIMP-1 (soluble endogenous MMP inhibi-
tor) and TIMP-2 (membrane-anchored and soluble MMP inhibitor) 
reduced the TMR fluorescence in HT1080 cells. 40 was tested in 
mice bearing HT1080 and MCF-7 tumors. Retention of 40 was 
observed in HT1080 tumors, with the highest uptake 60 min p.i., 
but not in MCF-7 tumors. Moreover, the fluorescent signal of 
HT1080 tumor slices was correlated with the fluorescent staining of 
MMP-2. 41 was tested in vitro and accumulated significantly higher 
in HT1080 cells than in MCF-7 cells. Furthermore, addition of 10 
M 1,10-phenanthroline decreased substantially the retention of 41 
in HT1080 cells. In vivo evaluation in mice bearing HT1080 and 
MCF-7 tumors showed a retention of 41 in HT1080 tumors, with 
the highest intensity 60 min p.i., contrary to MCF-7 tumors. Treat-
ment with 20 mg/kg/day of 1,10-phenanthroline three days before 
the microPET scan resulted in 1.3-, 3.6- and 3.3-fold higher uptake 
of HT1080 tumors than MCF-7 tumors at 15, 60 and 120 min. Ex 
vivo biodistribution data were in accordance with in vivo experi-
ments. Thus, 41 allowed visualizing specifically MMP-expressing 




 Huang et al. [75] developed an activatable dual modality 
(PET/fluorescent) imaging agent 42 (Fig. 21) which consists of 
three parts: first of all, a MMP cleavable peptide sequence PLGVR, 
which is specially cleaved by MMP-7, -9, -12 and -13. Besides, 42 
includes a pair of dye/quencher, with NIR Cy5.5 as a dye and 
BBQ650 as a fluorescence quencher group, which is nonfluores-
cent. Finally, the peptide was conjugated with DOTA for radiola-
belling with 
64
Cu. 42 exhibited quite high stability in PBS and 
mouse serum at 37
0
C for up to 24 hr. BBQ650-PLGVR-K(Cy5.5)-
E-K(DOTA)-OH was evaluated for its cleavage specificity by 
MMP-13 enzyme in vitro. The fluorescent intensity of this probe 
was time dependent, the signal has an 8.2-fold increase from 0 to 
120 min, which was blocked in the presence of a broad-spectrum 
MMP inhibitor (MMP inhibitor III). This fluorescent probe was 
tested in mice bearing U87MG human glioma xenograft tumors. 
The U87MG tumor was clearly visualized with high tumor-to-
background contrast. Besides, the fluorescence intensity increased 
during the scanning period. Preinjection with the MMP inhibitor III 
led to a lower intensity at the tumor site at each time point, which 
suggests specific uptake of this fluorescent probe. Due to the lim-
ited spatial resolution of NIRF, the quantitative technique PET was 
used in order to correct the enzyme activity obtained from optical 
imaging. In one mouse was injected the same amount of MMP-13 
enzyme at four different sites. At sites 1 and 3 were injected 15 Ci 
of 42 whereas at sites 2 and 4 were administered 2.5 Ci of 42. 
Coinjection of the MMP inhibitor III was performed at site 3 and 4. 
By considering the optical signal, the blocking effects were 38.33% 
for site 1 vs site 3 and 10.66% for site 2 vs site 4. By normalization 
of the fluorescence signal per unit of radioactivity, the real fluores-
cent signal at each inhibition site was calculated. The inhibition 
percentages at site 3 and site 4 were 79.6% and 79.7%, respectively. 
The blocking effect was more accurately quantified after the coreg-
istration of PET/fluorescence signals. To conclude, 42 allowed 
specific visualization of U87MG tumors in vivo. Moreover, the 
quantitative PET signal allowed correction of the enzyme activity 


















      hydantoin                    1,3,4-triazol-2-one                        imidazol-2-one 
Fig. (22). Structure of alternative ZBGs to the hydroxamate. 
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Table 4. clog P, log P, clog D and log D Values of Synthetic MMP Inhibitors/MMP Peptides 
MMP inhibitors / 
MMP peptides 
clog P log P clog D log D 
RP805 2.53    
6a [40]; [41] 0.228    
7 [42]; [43] 4.24    
8 [44]; [45] 3.76    
9 [46] 3.09    
10 [48] 3.89    
12a [50]; [51]    2.02 
13a [48] 2.40    
13b [48] 2.40    
13c [48] 1.79    
13d [48] 1.97    
13e [48] 1.97    
14a [53] 2.37    
14b [53] 2.37    
14c [53] 2.64    
14d [53] 2.94    
14e [53] 2.94    
14f [53] 2.59    
14g [53] 3.09    
14h [53] 3.09    
14i [53] 3.35    
15a [54] 1.40    
15d [54] 0.14    
16 [51]; [56]    1.34 
17 [50]; [57]    1.85 
18 [53]    0.60 
19 [47] 3.80    
20a [59] 3.46    
20b [59] 4.02    
20c [59] 4.02    
20d [59] 4.23    
20e [59] 4.23    
20f [59] 4.23    
20g [59] 3.90    
22 [60] 2.88    
23 [42]; [43] 5.48    
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MMP inhibitors / 
MMP peptides 
clog P log P clog D log D 
24 [44]; [45] 5.00    
25a [61] 3.58    
25b [61] 3.80    
25c [62] 2.80    
25d [62] 4.06    
26 [63] 3.80    
27 [65] 4.21    
28 [66]   2.88 2.15 
29 [67]   0.99 0.78 
31 [69]  0.36   
34 [71]  4.0   
35 [72]    -3.6 
 
PERSPECTIVES AND CONCLUSION 
In Vivo Models for the Evaluation of the MMP-targeting Probes 
 The regional distribution of radiolabelled MMPIs has been 
rather well-characterized in vascular imaging, particularly athero-





(HYNIC-RP805)(tricine)(TPPTS) 5, and [
123
I]I-HO-CGS 27023A 
15e exhibited specific binding in the aforementioned diseases. So 
far, most preclinical evaluation of radiolabelled MMPIs occurred 
only at the preliminary stage. The signal to noise ratios of most 
probes were rather low and comparisons of probe binding with ex 
vivo characterization of target expression (IHC or zymography) 
were rarely performed. Some work has been done in tumor models 
but very little work was done in models of inflammation (asthma, 
COPD, rheumatoid arthritis, etc). There is much opportunity for 
tracer evaluation in disease models other than atherosclerosis or 
aneurysm. 
Specific Activity 
 A high specific radioactivity of PET/SPECT probes may be 
required considering that natural TIMPs bind to the same domain as 
MMPIs [76] with a very high affinity in the picomolar range. TIMP 
competition for probe binding is probably severe since most radio-
labelled MMPIs have affinities in the nanomolar range with excep-
tion of the recently published compound 18. If possible, biological 
samples or experimental animals should be depleted of TIMPs be-
cause TIMPs tightly and irreversibly bind to active MMPs and will 
decrease the uptake of the radiolabelled probes. However, if radio-
labelled MMPIs would visualize the net balance of MMPs not oc-
cupied by TIMPs, this fraction might be a clinically important pa-
rameter, which could reflect the protease activity in the extracellu-
lar matrix. 
Affinity 
 The IC50 values of the reported synthetic MMP inhibitors and 
MMP peptides are summarized in (Table 3). The parent compound 
of [
99m
Tc]-(HYNIC-RP805)(tricine)(TPPTS) 5, RP805, exhibited 
affinity in the low nanomolar range. Since [
99m
Tc]-labelled RP805 
displayed specific binding in vivo and since the labeled probe 
probably has a decreased affinity compared to the parent com-
pound, a nanomolar probe affinity appears sufficient for SPECT 
imaging, at least in cardiovascular diseases.  
Lipophilicity 
 The clog P, log P, clog D and log D of the reported synthetic 
MMP inhibitors and MMP peptides are reviewed in (Table 4). As 
two third of MMPs are soluble, it is more logical to develop a hy-
drophilic MMPI. Moreover, some radiolabelled probes with a very 
high log P values such as 23 (5.48) which were developed have 
shown a very strong non-specific binding. Thus, log P values 
greater than 2.5 may better be avoided. 
Alternative to Hydroxamic Acid 
 Agrawal et al. [77] demonstrated the importance of the ZBG for 
MMPIs and as a result, modification of the ZBG has more effect 
than change of the substituents in the different pockets. So much 
effort has to be focused on the development of alternative ZBGs. 
Even though the hydroxamic acid is a potent ZBG, it has some 
drawbacks such as a difficult synthesis, metabolic instability and 
most importantly, a too high potency for zinc binding. Indeed the 
hydroxamate binds many zinc proteases and can also chelate metals 





fold stronger than Zn(II)). Other ZBGs which are more selective 
than hydroxamic acid have been designed and developed such as 
hydantoins, 1,3,4-triazol-2-ones and imidazol-2-ones (Fig. 22); [78] 
but labelled probes based on these structures were not yet tested in 
vivo. 
Pro/active MMP Binding 
 Many MMPIs bind to both active and pro-MMPs, for instance 
7, thus the binding of most MMPI is not activity-dependent. There-
fore the use of radiolabeled substrates [79], antibodies (e.g. [
99m
Tc]-
anti-MT1-MMP mAb [80]; [81]; [82]) or cell-penetrating peptides 
[83] should be considered as alternatives for MMP imaging. A 
complementary approach with a MMPI and a MMP antibody could 
also be performed to target the activity and the density of MMPs.  
 To conclude, there is much opportunity to design, synthesize 
and evaluate a new generation of probes targeting MMPs. 
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ABBREVIATIONS 
AA5 = Annexin A5  
ADAM = A disintegrin and metalloproteinase 
ApoE-/- = Apolipoprotein E  
COPD = Chronic obstructive pulmonary disease  
DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-
Tetraacetic acid 
DTPA = Diethylene triamine pentaacetic acid (or 
Pentetic acid) 
ECM = Extracellular matrix 
EGF = Epidermal Growth Factor 
FITC = fluorescein isothiocyanate 
HC = High-cholesterol 
HYNIC =  hydrazinonicotinamide
 
ID/g = Injected dose/gram 
IVC = Inferior vena cava 
LDLR-/- = Low-density-lipoprotein receptor  
LV = Left ventricular 
MADDAM = Metalloprotease and disintegrin dendritic 
antigen marker 
MI = Myocardial infarction 
MMP = Matrix metalloproteinase 
MMPI = Matrix metalloproteinase inhibitor 
MRI = Magnetic resonance imaging 
ND = Not determined 
NIR = Near infrared 
PBS = Phosphate-buffered saline 
PET = Positron emission tomography 
qRT-PCR = Quantitative real time polymerase chain 
reaction 
RCY = Radiochemical yield 
SAR = Structure-activity relationships 
SPECT = Single photon emission computed tomogra-
phy 
SUV = Standardized uptake value 
TACE = TNF alpha protease inhibitor 
TIMP = Tissue inhibitor of matrix metalloproteinase 
(t)MDC = (Transmembrane) metalloprotease-like, dis-
integrin-like, cystein-rich protein  
TMR = Tetramethylrhodamine 
TNF = Tumor necrosis factor 
TPPTS = Trisodium triphenylphosphine-3,3’,3’’-
trisulfonate 
TUNEL = Terminal deoxyribonucleotide transferase-
mediated nick-end labeling 
WT = Wild-type 
ZBG = Zinc binding group 
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